000			01960nam a2200265 4500
001			ESSALUD
005			20260805101217.0
007			ta
008			t pe ||||| |||| 00| 0 spa d
040			_aBMG
041			_aeng
100			_aHegedüs, Laszlo _953915
245			_aManagement of differentiated thyroid cancer
300			_apáginas: 2340-2355
520			_aModern risk-adapted management of thyroid cancer involves risk stratification as an active, dynamic process that begins with the detection of a thyroid nodule and continues throughout the clinical course of diagnosis, active surveillance or treatment, and follow-up. Rooted in clinicopathological staging, which can be further refined with the molecular risk characterization of the tumor, initial management plans are developed and modified over time on the basis of the natural history of the disease and the response to therapy. We present a clinical framework for therapeutic decision making that can be used to compare, contrast, and illustrate the relative risks, benefits, and patient preferences that are integral to the development of a personalized management plan. We examine examples of therapeutic decision making in active surveillance of low-risk papillary thyroid cancer, minimalist therapeutic management options for low- and intermediate-risk thyroid cancer, and systemic therapies for advanced thyroid cancer, showing how the therapeutic decision-making framework can be used to achieve informed consensus and management recommendations.
650			_aMEDICINA DEL ADOLESCENTE _95533
650			_aCANCER INFANTIL _953916
650			_aHEMATOLOGÍA _97422
650			_aONCOLOGÍA _912240
650			_aHEMATOLOGÍA _97422
700			_aWirth, Lori J. _953917
700			_aTuttle , R. Michael _953918
773	0		_022717 _922640 _dMassachusetts NEJM Group _oNEJM007 _tThe New England Journal of Medicine _wESSALUD _x0028-4793
942			_cARTICULOS _e2026-08-03 _zSQB
999			_c22770 _d22770